UCB and Biogen's Lupus Drug Shows Promising Phase 3 Results

Dapirolizumab pegol meets primary endpoint in late-stage study, with a second trial set to begin later this year.

The Phase 3 PHOENYCS GO study demonstrated significant clinical improvement in patients with moderate-to-severe systemic lupus erythematosus (SLE).
Dapirolizumab pegol, combined with standard-of-care treatments, reduced disease activity more effectively than placebo.
This success follows an earlier Phase 2 failure, surprising many in the medical community.
UCB and Biogen plan to initiate a second Phase 3 trial, PHOENYCS FLY, in 2024.
Detailed results will be presented at an upcoming medical conference, highlighting the potential impact on SLE treatment options.